CLINICAL STUDY ON TUBERACTINOMYCIN-N, A NEW ANTIBIOTIC

Abstract

Authors reported the results of Tuberactinomycin (TUM) used for pulmonary tuberculosis patients who failed to respond to the treatment by the usual primary and secondary anti-tu-berculosis drugs (Kekkaku, Vol.46, No.3, 1971). Tuberactinomycin was isolated from the culture filtrate of Streptomyces griseoverticillatus var. tuberacticus. Tuberactinomycin-N (TUM-N) was isolated from mutant strain (N 6-130) of original strain and showed the less auditory impairment for guinea pig than kanamycin, capreomycin, viomycin and tuberactinomycin.
This paper presents the results of Tuberactinomycin-N used for pulmonary tuberculosis patients who failed to respond to the previous treatment.
Usually 1g of TUM-N was injected intramuscularily once a day. For the initial 3 months, TUM-N was injected daily followed by the TUM-N twice a week. The patients were treated by TUM-N combined with one or more drugs previously not used. In many cases rifampicin and ethambutol were combined with TUM-N. 27 patients were treated by TUM-N for more than one month. Bacteriological examinations by both smear and culture were performed twice a month. The X-ray photography, the urine and blood examination and liver function test were performed every month. The audiometry was also performed once a month.
The results were summarized asfollows:
(1) The bacteriological findings by smear of 17 smear positive casesduring TUM-N treatment were shown in Table 1. The smear negative rate was 53.3% at third month and 80% at sixth month.
(2) The bacteriological findings by culture of 15 culture positive cases were shown in Table 2. As seen in this table, the culture negative rate was 64.3% at third and 100% at sixth month.